nach oben

Diabetologia

Erschienen in:

01.06.2004 | Commentary

The time has come to target connective tissue growth factor in diabetic complications

verfasst von: S. M. Twigg, M. E. Cooper

Erschienen in: Diabetologia | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Excerpt

Dysregulation of growth factors is amongst the changes that occur in cells and tissues in diabetes. As growth factors commonly control essential biological functions, it follows that they may be critical in causing the end-organ complications of diabetes [1]. Consequently, identifying the key growth factor(s) that cause a particular type and stage of diabetic tissue damage is of potential importance in preventing and treating diabetes complications. …

Flyvbjerg A (2000) Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43:1205–1223

Brigstock DR (2003) The CCN family: a new stimulus package. J Endocrinol 178:169–175PubMed

Gore-Hyer E, Shegogue D, Markiewicz M et al. (2002) TGF-beta and CTGF have overlapping and distinct fibrogenic effects on human renal cells. Am J Physiol Renal Physiol 283:F707–F716PubMed

Dolan V, Hensey C, Brady HR (2003) Diabetic nephropathy: renal development gone awry? Pediatr Nephrol 18:75–84PubMed

Chen CC, Chen N, Lau LF (2001) The angiogenic factors Cyr61 and connective tissue growth factor induce adhesive signaling in primary human skin fibroblasts. J Biol Chem 276:10443–10452CrossRefPubMed

Shimo T, Nakanishi T, Nishida T et al. (1999) Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 126:137–145PubMed

Murphy M, Godson C, Cannon S et al. (1999) Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274:5830–5834PubMed

Riser BL, Denichilo M, Cortes P et al. (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25–38PubMed

Wang S, Denichilo M, Brubaker C, Hirschberg R (2001) Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 60:96–105PubMed

10.

Ito Y, Aten J, Bende RJ et al. (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853–861PubMed

11.

Candido R, Forbes JM, Thomas MC et al. (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785–792

12.

Candido R, Jandeleit-Dahm KA, Cao Z et al. (2002) Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 106:246–253CrossRefPubMed

13.

Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M (2004) Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by ACE inhibition. Endocrinology 145:860–866CrossRefPubMed

14.

Blom IE, Goldschmeding R, Leask A (2002) Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21:473–482CrossRefPubMed

15.

Twigg SM, Cao Z, McLennan SV et al. (2002) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143:4907–4915CrossRefPubMed

16.

Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M (2003) Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circ Res 1081:499–505

17.

Abreu JG, Ketpura NI, Reversade B, De Robertis EM (2002) Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 4:599–604

18.

Inoki I, Shiomi T, Hashimoto G et al. (2002) Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 16:219–221PubMed

19.

Ziyadeh FN, Hoffman BB, Han DC et al. (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020PubMed

20.

Caldwell RB, Bartoli M, Behzadian MA et al. (2003) Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 19:442–455CrossRefPubMed

21.

Twigg SM, Joly AH, Chen MM et al. (2002) Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143:1260–1269CrossRefPubMed

22.

Lam SC, Geest RN van der, Verhagen NA et al. (2003) Connective tissue growth factor and igf-I are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes 52:2975–2983PubMed

23.

Abdel-Wahab N, Weston BS, Roberts T, Mason RM (2002) Connective tissue growth factor and regulation of the mesangial cell cycle: role in cellular hypertrophy. J Am Soc Nephrol 13:2437–2445PubMed

24.

Gupta S, Clarkson MR, Duggan J, Brady HR (2000) Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 58:1389–1399CrossRef

25.

Goldschmeding R, Aten J, Ito Y, Blom IE, Rabelink T, Weening JJ (2000) Connective tissue growth factor: just another factor in renal fibrosis? Nephrol Dial Transplant 15:296–299CrossRefPubMed

26.

Ivkovic S, Yoon BS, Popoff SN et al. (2003) Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130:2779–2791CrossRefPubMed

27.

Mori R, Kondo T, Ohshima T, Ishida Y, Mukaida N (2002) Accelerated wound healing in tumor necrosis factor receptor p55-deficient mice with reduced leukocyte infiltration. FASEB J 16:963–974CrossRefPubMed

28.

Riser BL, Cortes P, DeNichilo M et al. (2003) Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: preliminary report. Kidney Int 64:451–458CrossRefPubMed

29.

Gilbert RE, Akdeniz A, Weitz S et al. (2003) Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care 26:2632–2636PubMed

30.

Adler SG, Kang SW, Feld S et al. (2002) Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? Am J Kidney Dis 40:184–188CrossRefPubMed

Titel: The time has come to target connective tissue growth factor in diabetic complications
verfasst von: S. M. Twigg
M. E. Cooper
Publikationsdatum: 01.06.2004
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 6/2004
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-004-1423-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2004

Physiological hyperinsulinaemia increases intramuscular microvascular reactive hyperaemia and vasomotion in healthy volunteers

Peroxisome proliferator-activated receptor γ gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries

Effects of metoprolol on QT interval and QT dispersion in Type 1 diabetic patients with abnormal albuminuria

Nerve growth factor supplementation reverses the impairment, induced by Type 1 diabetes, of hindlimb post-ischaemic recovery in mice

Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells

Diabetes mellitus and risk of prostate cancer: a meta-analysis